Clinical Trial

Cross-sectional Study of Sleep Disturbance in Hong Kong Children With Cancer Comparing With Healthy Counterparts and Children With Other Chronic Diseases

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 17, 2025 (before its estimated January 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Sleep disturbances are prevalent among children with chronic illnesses, yet the specific impact of cancer on sleep remains underexplored. This prospective and cross-sectional study aims to evaluate the prevalence, severity, and characteristics of sleep disturbances in Chinese children with cancer compared to healthy peers and children with other chronic diseases. By leveraging validated sleep assessment tools and parental reports, the goal is to identify unique challenges faced by children with cancer. Results might influence the design of personalized interventions aimed at enhancing the overall well-being of children with cancer. This study will enroll Chinese children aged 6 to 18 years, divided into three distinct groups based on their health status: children with cancer, children with other chronic illnesses, and healthy children. A total sample size of 150 participants (50 per group) will be targeted to ensure adequate statistical power for comparative analyses. Recruitment will occur at Hong Kong Children's Hospital or the cancer and chronic illness groups, and healthy children will be recruited from healthy siblings of participants or the healthy children of hospital staff with specific inclusion and exclusion criteria applied to each group to maintain homogeneity and minimize confounding variables.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-08.
Trial Details
NCT Number NCT07122921
Lead Sponsor Chinese University of Hong Kong
Conditions Sleep, Sleep Disturbances in Children, Sleep Disturbances
Enrollment 150 participants
Start Date 2025-07-02
Primary Completion 2026-01-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-17